Molecular Partners (MOLN)
NASDAQ:MOLN
Want to see MOLN full AI Analyst Report?
MOLN Stock Chart & Stats
$4.20
-$0.03(-0.55%)
At close: 4:00 PM EST
$4.20
-$0.03(-0.55%)
Day’s Range― - ―
52-Week Range$3.41 - $5.36
Previous CloseN/A
Volume8.30K
Average Volume (3M)2.31K
Market Cap
$167.62M
Enterprise Value$31.76M
Total Cash (Recent Filing)$93.06M
Total Debt (Recent Filing)$3.64M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding40,374,640
10 Day Avg. Volume2,377
30 Day Avg. Volume2,311
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)1.60
Price to Sales (P/S)0.00
P/FCF Ratio-2.48
Enterprise Value/Market Cap0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.01
Enterprise Value/Ebitda-0.53
Forecast
1Y Price Target
$11.00Price Target Upside161.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.59
Revenue Forecast (FY)$6.83M
Bulls Say, Bears Say
Bulls Say
Isotope FlexibilityDARPin platform's isotope-agnostic design enables exploration of multiple radioactive payloads, broadening therapeutic and imaging options across the pipeline.
Preclinical EfficacyLead candidate MP0712 showed high target specificity and substantial tumor regressions in preclinical models, supporting its potential for meaningful clinical responses.
Supply AccessA supply agreement with an isotope specialist improved access to lutetium and related isotopes, reducing a prior development bottleneck for radiopharmaceutical programs.
Bears Say
Biodistribution UncertaintyInvestor questions about biodistribution for the DLL3-targeted radioDARPin suggest the construct may require exploration of longer-lived isotopes or reformulation, complicating development plans.
Financing RiskAvailable cash appears limited relative to ongoing development needs, creating the possibility that additional financing will be required and dilute existing shareholders.
Program ReprioritizationReprioritization of a program toward combination development with an external partner could slow independent advancement and delay expected clinical readouts.
Molecular Partners News
MOLN FAQ
What was Molecular Partners’s price range in the past 12 months?
Molecular Partners lowest stock price was $3.41 and its highest was $5.36 in the past 12 months.
What is Molecular Partners’s market cap?
Molecular Partners’s market cap is $167.62M.
When is Molecular Partners’s upcoming earnings report date?
Molecular Partners’s upcoming earnings report date is Aug 31, 2026 which is in 115 days.
How were Molecular Partners’s earnings last quarter?
Molecular Partners released its earnings results on Mar 12, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.4 by -$0.03.
Is Molecular Partners overvalued?
According to Wall Street analysts Molecular Partners’s price is currently Undervalued.
Does Molecular Partners pay dividends?
Molecular Partners does not currently pay dividends.
What is Molecular Partners’s EPS estimate?
Molecular Partners’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Molecular Partners have?
Molecular Partners has 40,374,640 shares outstanding.
What happened to Molecular Partners’s price movement after its last earnings report?
Molecular Partners reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.4. Following the earnings report the stock price went down -10.403%.
Which hedge fund is a major shareholder of Molecular Partners?
Currently, no hedge funds are holding shares in MOLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
MOLN Stock 12 Month Forecast
Average Price Target
$11.00
▲(161.90% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
0.04% Other Institutional Investors
99.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---